2 completed, 1 withdrawn. 1 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow XWPharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study Valiloxybate, Placebo - Parkinson Disease, Excessive Daytime Somnolence | Phase 2 | Withdrawn | XWPharma | 2021-11-01 | 2025-03-19 | |
| Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults XW10508, Placebo - Healthy Volunteers | Phase 1 | Completed | XWPharma | 84 | 2021-07-13 | 2022-11-04 |
| Pharmacokinetics, Safety, and Tolerability of Various XW10172 Oral Formulations in Healthy Adult Volunteers XW10172 - Healthy | Early Phase 1 | Completed | XWPharma | 46 | 2020-11-29 | 2022-11-04 |
Disorders of Excessive Somnolence (1) · Parkinson Disease (1)
Australia (2)
Daniel M. Canafax, PharmD (2) · Daniel M Canafax, PharmD (1)